Migraine And Headache

Ajovy Injection Approved for Migraine Prevention in Adults

By September 17, 2018

The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.

New Device Available for Patients With Episodic Cluster Headache, Migraine

By August 02, 2018

The Sapphire has a rechargeable and reloadable fill capacity; it can be activated monthly by inputting a unique, prescription-only authorization code, delivered via a radio-frequency identification card that is mailed to the patient.

Butalbital/APAP Capsules Launched for Complex Tension Headache

By August 01, 2018

The label includes a Boxed Warning describing the risk of hepatotoxicity associated with APAP. Most cases of liver injury were associated with APAP doses >4000mg daily and often involved >1 APAP-containing product.

Risk of Cochlear Disorders Up With History of Migraine

July 18, 2018

For the migraine and non-migraine cohorts, the incidence rates of cochlear disorders were 81.4 and 29.4 per 1 million person-years, respectively.

OnabotulinumtoxinA Safer, More Effective for Headache Prevention Than Topiramate

June 29, 2018

This randomized, open-label study examined participant reported outcomes, safety, and tolerability of onabotulinumtoxinA and topiramate in adults with chronic migraines.

Fremanezumab Chronic Cluster Headache Study Discontinued

By June 15, 2018

Fremanezumab, an anti-CGRP monoclonal antibody, is currently being reviewed by the Food and Drug Administration (FDA) as a quarterly or monthly injection for the preventive treatment of migraine in adults.

Antiepileptic Treatment Shows Efficacy in Reducing Migraine Frequency

June 12, 2018

The antiepileptic drug levetiracetam may represent an effective prophylactic treatment option for episodic migraine.

Galcanezumab Beneficial for Patients With Episodic Migraine, Says Study

May 31, 2018

A total of 858 adults with at least a 1-year history of migraine, 4 to 14 migraine headache days per month, and a mean of at least 2 migraine attacks per month within the past 3 months received once-monthly treatments for 6 months and were followed up for 5 months after the last injection.

First-of-its-Kind Migraine Drug Gets FDA Approval

By May 18, 2018

The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).

Fremanezumab effective in preventing episodic migraine

May 17, 2018

In this randomized controlled trial, Fremanezumab slightly decreased the amount of headache free days in those with episodic migraines compared to placebo.

Fremanezumab Linked to Fewer Monthly Migraine Days

May 16, 2018

The researchers found that over 12 weeks, mean migraine days per month decreased from 8.9 to 4.9 days, from 9.2 to 5.3 days, and from 9.1 to 6.5 days in the fremanezumab monthly dosing group, the fremanezumab single-higher-dose group, and the placebo group, respectively.

Galcanezumab Effective in Phase 3 Episodic Cluster Headache Study

By May 15, 2018

The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.

Antidepressant Medications and Headache: Is There a Link?

By May 03, 2018

Compared to placebo, selective serotonin reuptake inhibitors (SSRIs) were associated with a significantly higher risk of headache (risk ratio [RR] 1.06, 95% CI: 1.00 to 1.13; P =.045).

Results From Phase 3 Trial of Migraine Tx Ubrogepant Released

By April 27, 2018

Results showed that 14.3%, 20.7% (P=.0285), and 21.8% (P=.0129) achieved pain freedom in the placebo, ubrogepant 25mg dose, and 50mg dose groups, respectively.

Erenumab Shows Promise for Hard-to-Treat Migraine

April 19, 2018

"Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief," Reuter said in a statement.

FDA-Approved App Allows Clinicians to Objectively Measure Balance

By April 18, 2018

The application assesses 3 key balance metrics: (1) double stance, (2) right tandem stance, and (3) left tandem stance.

Patient Develops Thunderclap Headaches After Consuming 'Carolina Reaper'

By April 10, 2018

The authors note that this appears to be the first case of RCVS secondary to pepper or cayenne ingestion.

Noninvasive Brain Stimulation May Help Prevent Migraines

April 04, 2018

"This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention," the authors write.

Novel Nasal Spray for Migraine Attacks to Be FDA Reviewed

By April 02, 2018

DFN-02 was evaluated in a multicenter, double-blind, randomized, placebo-controlled study (N=107) which showed it was effective in treating pain and associated symptoms during a migraine attack and in reducing attack-related functional disability.

Migraine Treatment With Needle-Free Delivery System No Longer Available

By February 27, 2018

Both strengths of Sumavel DosePro have now been discontinued.

Serotonin Syndrome Risk Assessed With Concomitant Triptan, SSRI/SNRI Use

February 27, 2018

Researchers question FDA advisory warning on risk of concomitant use

Positive Results for Ubrogepant in Phase 3 Migraine Trial

By February 06, 2018

A total of 1,327 migraine patients were treated in the study for a single migraine attack. At 2 hours after migraine attack, 19.2% (n=423) and 21.2% (n=448) of ubrogepant 50mg and 100mg were pain free, respectively.

Migraines and Cardiovascular Disease: What's the Link?

February 01, 2018

There were positive associations for migraine with myocardial infarction, ischemic stroke and hemorrhagic stroke, venous thromboembolism, and atrial fibrillation or flutter.

GammaCore Approved for the Acute Treatment of Migraine Pain

By January 29, 2018

The new approval for migraine patients was supported by the PRESTO trial, a multicenter, randomized, double-blind, sham-controlled trial.

Erenumab Effective in Migraine Patients With Multiple Treatment Failures

By January 23, 2018

Aimovig is a fully human monoclonal antibody, designed to selectively block the calcitonin gene-related peptide (CGRP) receptor.

Significant Migraine Risk Reduction Seen With Eptinezumab in Phase 3 Trial

By January 08, 2018

The 'PROMISE 2' study included 1,072 patients who were randomized to receive eptinezumab (300mg or 100mg), or placebo once every 12 weeks.

FDA to Review Fremanezumab for Migraine Prevention

By December 19, 2017

Results from the CM trial found that the fremanezumab arm experienced statistically significant reduction in the number of monthly headache days of at least moderate severity vs. placebo.

Successful Treatment of Migraine With Antiviral/NSAID Combo

By December 14, 2017

Previous literature has speculated on an association between migraine headache and HSV.

FDA to Review Galcanezumab for Migraine Prevention in Adults

By December 11, 2017

The application includes data from three Phase 3 trials; Evolve-1, Evolve-2 (6 months) and Regain (3 months).

ASHP: Revised Standards can Build Framework for Opioid Stewardship

December 06, 2017

The new and revised standards from The Joint Commission were published in July 2017 to address some of the issues associated with over-prescribing and lack of monitoring.